Kornimate/medical-research-clean huggingface dataset:
effect of beta-adrenergic blockers on cardiac function, systemic and splanchnic haemodynamic and kidney function in cirrhotic patiets with refractory ascites

Conditions: Hepatic Cirrhosis

Summary: multicentric, observational and prospective study with two groups of treatment: refractory ascites and non-refractory ascites. all patients should be prescribed beta-adrenergic blockers as primary or secondary profilaxis for variceal bleeding.


Eligibility criteria:
inclusion criteria: * patients aged 18-80 * patients previously prescribed with beta-blockers * any type of hepatic cirrosis that has been diagnosed by clinical, analytic and image criteria * mild to serious ascites. classification on refractory or non-refractory ascites depends on the patient´s response to diuretic treatment. refractory ascites is defined by the ascites´board international criteria as the lack of response, ascites recurrency or complications occurrence by diuretic drugs uptake * esophageal varicose vein in which beta blockers treatment is indicated as primary or secondary prophylaxis. primary prophylaxis is indicated for big esophageal varicose veins, small varicose veins with red signs or varicose veins in patients with b-c child-pugh stage. secondary prophylaxis is indicated for all those patients that have previously presented varicose bleeding. * patients giving a written consent to participate in the study after having received enough information about the design, objectives and risks. exclusion criteria: * hepatocellular carcinoma \>5 cm * total portal vein thrombosis or cavernous transformation of the portal vein * insuficiencia renal (creatinina sérica \>3 mg/dl). * kidney insufficiency (seric creatinine \>3 mg/dl) * contraindications to beta-blockers: cardiac or breathing insufficiency, auricular-ventricular blocking grade \>1. * anticoagulant treatment * patients with a intrahepatic portosystemic shunt * beta-blockers hypersensitivity * pregnancy and breastfeeding * women of childbearing age must commit to undergo an effective contraception during the treatment and at least one month after finishing it. * patients with severe controlled or not controlled psychiatric condition * patients´ lack of commitment to follow all visits.

Keywords: hepatic cirrhosis ascites beta blockers treatment
transversus abdominis plane(tap) block, local infiltration and intravenous dexketoprofen in inguinal hernia repair

Conditions: Inguinal Hernia

Summary: this study evaluates the compare the effects of ultrasound guided tap block, local anesthetic infiltration to the incision line and intravenous dexketoprofen on postoperative analgesic efficacy and rescue tramadol consumption in inguinal hernia repairs.

currently, multimodal techniques are used in inguinal hernia repairs in addition to pharmacological and regional techniques for postoperative analgesia.tap block is performed on the principle of hydrodissection of the fascia between the internal oblique and transversus abdominis muscles of the abdominal wall muscles with local anesthetic drugs. local anesthetic drugs provide analgesic effect up to 24 hours in the postoperative period by blocking the t6-l1 nerves in the facial plane. local anesthetic infiltration which is one of the regional anesthetic techniques, is another method of postoperative analgesia. intravenous analgesic drug is also used as pharmacological postoperative analgesia method in most clinics.

Eligibility criteria:
inclusion criteria: * subject who aged 18-75 years * american society of anesthesiologist (asa) i-iii * subject undergoing unilateral or bilateral inguinal hernia repair exclusion criteria: * subject under 18 and over 75 years of age * asa iv * history of allergy to agents * analgesic drug use in the last 48 hours * morbid obese (bmi\> 35) * confusion * coagulopathy * local infection at the injection site * subject with heart, lung, hematologic, metabolic and endocrine disease * subject who did not want to be included in the study * subject who refused the spinal anesthesia * subject who failed the spinal anesthesia
nbi-1065845-mdd3025: study to assess the efficacy and safety of nbi-1065845 as an adjunctive treatment in participants with major depressive disorder (mdd)

Conditions: Major Depressive Disorder

Summary: the study will evaluate the efficacy of nbi-1065845 compared with placebo as an adjunctive treatment in participants with mdd on improving symptoms of depression.


Eligibility criteria:
key inclusion criteria: * participant has a primary diagnosis of recurrent mdd (moderate or severe) or persistent depressive disorder. * participant has had an inadequate response to oral antidepressant treatments in the current episode of depression. * participant must have been taking oral antidepressants for at least 8 weeks and is willing to continue the same oral antidepressants at the same dose and frequency of administration throughout participation in the study. * total hamilton depression rating scale-17 item (ham-d17) score ≥22 at screening and at study baseline (day 1). * willing and able to comply with all study procedures and restrictions in the opinion of the investigator. key exclusion criteria: * a current or prior psychiatric disorder diagnosis in the last 1 year that was the primary focus of treatment other than mdd. * are considered by the investigator to be at imminent risk of suicide or injury to self or others. * participants depressive symptoms have previously demonstrated nonresponse to electroconvulsive therapy (ect) in the current major depressive episode.

Keywords: mdd depression major depressive disorder nbi-1065845 tak-653 madrs
promoting safer sex in hiv+ homosexual and bisexual men who use methamphetamine

Conditions: HIV Infections; STDs; Methamphetamine Abuse

Summary: this project studies the effectiveness of a sexual risk reduction intervention among hiv+ men who have sex with men (msm) and who use methamphetamine.


Eligibility criteria:
inclusion criteria: * hiv+ * men who have sex with men exclusion criteria:

Keywords: hiv stds methamphetamine abuse msm
serum and tissue cefazolin concentrations in normal weight patients undergoing cesarean delivery.

Conditions: Infection; Cesarean Delivery; Antibiotic Prophylaxis

Summary: patients undergoing cesarean delivery (c-section) with a body mass index of 30 or less will be given either 2 grams or 4 grams of an antibiotic before surgery. the antibiotic is intended to prevent infection from the surgery. it is unknown what the best dose for the usual medicine used for this purpose (an antibiotic medicine called cefazolin). samples of the tissue just under the skin will be biopsied at the time the incision is made and at the time the cut is stitched or stapled closed. a sample of the muscle of the womb will be taken as the womb is stitched closed after the delivery. blood tests will be done at the start and end of surgery to test the antibiotic level. a blood sample will be taken from the umbilical cord after the baby has been delivered and the umbilical cord has been cut. the umbilical cord blood sample will be tested for the antibiotic level. these tests will be used to find out if the usual dose of medicine is enough or if more medicine is needed to prevent infection in normal weight women undergoing c-sections.


Eligibility criteria:
inclusion criteria: 1. age 18 years or above 2. body mass index (bmi) of 30 or less, as calculated from the height and weight at the first prenatal visit 3. undergoing cesarean delivery exclusion criteria: 1. bmi greater than 30. 2. not undergoing cesarean delivery. 3. age less than 18 years. 4. pre-existing infection. 5. allergy to cephalosporin medications or a history of an anaphylactic reaction to penicillin. 6. cesarean delivery being performed under emergent circumstances

Keywords: infection cesarean delivery antibiotic prophylaxis cefazolin dosing
doxercalciferol before surgery in treating localized prostate cancer

Conditions: Prostate Cancer

Summary: rationale: doxercalciferol may be an effective way to treat localized prostate cancer before surgery. purpose: randomized phase ii trial to study the effectiveness of giving doxercalciferol before surgery in treating patients who have localized prostate cancer.

objectives: * determine whether doxercalciferol modulates intermediate endpoint biomarkers in the development of prostate cancer in patients with localized prostate cancer. * assess the toxicity of this drug in these patients. outline: this is a randomized, open-label, multicenter study. patients are randomized to one of 2 arms. * arm i: patients receive doxercalciferol once daily for 28 days. patients then undergo prostatectomy. * arm ii: patients undergo observation for 28 days. patients then undergo prostatectomy. projected accrual: a total of 60 patients (30 per arm) will be accrued for this study within 18 months.

Eligibility criteria:
disease characteristics: * histologically or cytologically confirmed localized adenocarcinoma of the prostate * candidate for prostatectomy patient characteristics: age: * 21 and over performance status: * not specified life expectancy: * not specified hematopoietic: * wbc at least 4,000/mm\^3 * platelet count at least 100,000/mm\^3 hepatic: * bilirubin no greater than 1.4 mg/dl * ast no greater than 3 times normal renal: * creatinine no greater than 2.0 mg/dl * calcium no greater than 10.2 mg/dl * no idiopathic urinary calcium stone disease prior concurrent therapy: biologic therapy: * not specified chemotherapy: * not specified endocrine therapy: * no prior hormonal therapy for prostate cancer * no concurrent hormonal therapy, including luteinizing hormone-releasing hormone agonists, antiandrogens, glucocorticoids, ketoconazole, finasteride, diethylstilbestrol, or progestins radiotherapy: * no prior brachytherapy or external beam radiotherapy for prostate cancer surgery: * see disease characteristics other: * at least 7 days since prior vitamin d therapy or calcium supplements * no other concurrent vitamin d analogues or calcium supplements * no concurrent magnesium-containing antacids * no concurrent thiazide-containing diuretics * no concurrent phenytoin, phenobarbital, glutethimide, digoxin, or digitalis

Keywords: adenocarcinoma of the prostate stage i prostate cancer stage ii prostate cancer
open-label, long-term safety study of secukinumab in polymyalgia rheumatica (pmr)

Conditions: Polymyalgia Rheumatica

Summary: the purpose of this extension study is to assess the safety and tolerability of secukinumab when administered long-term in patients with polymyalgia rheumatica.

the study will consist of an up to 4-week screening period, an up to 2-year treatment period which includes two treatment periods, and a 16-week treatment-free follow-up period (20 weeks post last dose of secukinumab). treatment period: there will be two treatment periods (tps): tp1 will be from the first dose administration of secukinumab (baseline) to week 24, where visits will occur every 4 weeks, and tp2 will be from post week 24 visit (post-dose) to up to 2 years. participants will return to the study site every 4 weeks from baseline until week 24 (weeks 16 and 20 visits are optional on-site visits and needed when participants are unwilling/uncomfortable to self-administer study treatment at home/offsite), then every 12 weeks afterwards in tp2 for resupply of study medication but may return earlier if needed (i.e., those participants who are unwilling/uncomfortable to self-administer study treatment can continue to visit site every 4 weeks for drug administration if they wish to do so). follow-up period: an eos visit (20 weeks after last administration of secukinumab) will be done for all participants, regardless of whether they complete the entire study as planned, or they discontinue prematurely.

Eligibility criteria:
inclusion criteria: * participants who have completed 52-week treatment period as per protocol in a novartis study of secukinumab in pmr patients (the "core study" - study cain457c22301), and * who have experienced a relapse during the treatment-free follow-up period of the core study, and * who have not been on rescue treatment. * the participant would potentially derive benefit from secukinumab, and the benefit outweighs the risk, based on the investigator's judgement. exclusion criteria: * use of prohibited medications, as specified in the protocol * history of ongoing, chronic or recurrent infectious disease (i.e., human immunodeficiency virus (hiv), hepatitis b (hbv), hepatitis c (hcv), active tuberculosis infection (tb)) * history of lymphoproliferative disease or any known malignancy or history of malignancy of any organ system within the past 5 years (except for basal cell carcinoma or actinic keratosis that have been treated with no evidence of recurrence in the past 3 months carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed). * live vaccinations (e.g., monkey pox vaccine, oral polio vaccine, varicella/zoster vaccines) within 6 weeks prior to baseline * subjects whose participation in the extension study could expose them to an undue safety risk

Keywords: polymyalgia rheumatica (pmr) secukinumab monoclonal antibody subcutaneous (s.c.) extension long-term safety replenish
eye alignment and eye control changes through follow up period after application of eye exercises post strabismus surgery

Conditions: Strabismus; Intermittent

Summary: the aim of this study is to determine the patient status through its follow up period and weather the eye alignment and eye control are as the same as the last physiotherapy treatment session or there is any deterioration of them.

this study is quantitative cohort observational study. the study depends on following a group of participants over a period of time ( 2 months after completed physiotherapy training program for 3 months to improve eye alignment and eye control post strabismus surgery ). through the study, there is observation to the changes in certain quantitative variables ( eye alignment and eye control ).

Eligibility criteria:
inclusion criteria: * patients are both males and females. * their age will range from (5-15) years. * all patients received physiotherapy training for improving eye alignment and eye control. * patients applied the physiotherapy rehabilitation program for 3 months with the physiotherapist. * all patients complete their physiotherapy training sessions for improving eye alignment and eye control * all patients have a history of strabismus surgery. * intermittent exotropia was the type of strabismus which included to the study. exclusion criteria: * - patient who didn't receive physiotherapy training program for improving eye control and eye alignment post strabismus surgery. * patient who didn't complete the physiotherapy training program for 3 months. * muscular disorders that will impair performance during training. * any organic lesion in the eye. * neurological disorders. * malignant conditions. * psychiatric illness, severe behavior or cognitive disorders.
an observational study on the prevalence of human papillomavirus types in women in the kingdom of bahrain

Conditions: Human Papillomavirus Infection

Summary: the purpose of this study is to determine the human papillomavirus (hpv) prevalence and hpv type distribution among women ≥ 20 years of age attending routine cervical screening and among women ≥ 16 years of age presenting for post-natal check up in the kingdom of bahrain.


Eligibility criteria:
inclusion criteria: * women ≥ 20 years of age attending a clinic for routine cervical screening or * women ≥ 16 years of age presenting for post-natal check-ups * women providing a cervical sample * written informed consent or oral-witnessed thumb printed informed consent obtained from the subject exclusion criteria: * referral for abnormal cervical sample at the current visit * abundant menstrual bleeding or vaginal discharge not allowing appropriate screening to be performed (note: enrolment can be delayed until this condition is resolved) * pregnant women * history of hysterectomy * known diagnosis of immunosuppression, or patient on immunosuppressives * having received one or more doses of human papillomavirus vaccine prior to participating in the study
negative predictive value of drug provocation tests to beta-lactams

Conditions: Drug Hypersensitivity

Summary: patients with a complete drug allergy work-up to betalactam antibiotics were contacted (by mail) and asked to answer a questionnaire regarding the tolerance upon readministration of a negatively tested beta-lactam.


Eligibility criteria:
inclusion criteria: * elderly patients with at least 5 years at the time of consultation for allergy suspected allergy to beta-lactam antibiotics in the university hospital of montpellier and with a negative provocation test to a betalactam * the patient or the patient's legal representatives are not their opposition to participate in this study * the patient must be affiliated or beneficiary in a health insurance system exclusion criteria: * the patient is exclusion period determined by a previous study * the patient is under judicial protection, guardianship or curatorship * the patient or the patient's legal representatives do not read fluently the french language

Keywords: drug hypersensitivity betalactam drug provocation test
an add-on study of e2007 in patients with refractory partial seizures uncontrolled with other anti-epileptic drugs (aeds)

Conditions: Refractory Partial Seizures

Summary: the purpose of this study is to explore the maximum tolerated dose of e2007 in japanese patients with refractory partial seizures which are uncontrolled with other anti-epileptic drugs (aeds). thirty patients will receive e2007 (dose escalating to the maximum of 12 mg per day). the dose of e2007 will be adjusted during 6 weeks. subsequently, the dose will be fixed and maintained during 4 weeks.


Eligibility criteria:
inclusion criteria: 1. male or female aged between 20 and 64 years old. 2. patients diagnosed with partial seizure (including secondarily generalized seizure). 3. patients who have at least 3 counts of partial seizures during the previous 4 weeks prior to observation start and no seizure-free for 21 days during 8 weeks before the treatment start based on medical records. simple partial seizure without motor signs will not be counted. 4. patients who have been treated for at least 12 weeks but confirmed to be uncontrolled with more than one standard aed for 2 years. 5. patients treated with stable doses of up to three aeds. only one cytochrome p450 (cyp) 3a4 inducer shown below will be allowed for concomitant use: * carbamazepine * phenytoin * phenobarbital * primidone 6. patients on stable dose of anti-depressants, anti-anxiety drugs, or mood stabilizers from before 8 weeks. exclusion criteria: 1. patients with present or a history of lennox-gastaut syndrome. 2. patients with present generalized seizures (e.g., absence, myoclonic). 3. patients with a history of status epilepticus within 1 year. 4. patients with seizure clusters where individual seizure cannot be counted within 8 weeks. 5. patients with a history of psychogenic seizure. 6. patients who underwent surgical operation for epilepsy within 2 years. 7. patients using rescue benzodiazepines at least twice in a 4-week duration within 8 weeks (if 1 or 2 doses over 24-hour period considered one-time rescue). 8. patients whose alanine aminotransferase (alt) or aspartate aminotransferase (ast) at enrollment in observation period exceeds 1.5-fold the upper limit of normal (uln), but those whose alt or ast are constantly higher than uln, they can enroll if alt or ast remain in 3-fold the uln. 9. patients with significant active hematological disease; white blood cell (wbc) count \</=2500/ul or neutrophil count \</=1000 ul. 10. patients on anti-psychotics or who have psychotic disorder and/or psychotic disorder(s) or unstable recurrent affective disorder(s) with a history of suicidal attempt within 2 years. 11. patients who operate heavy equipment or drive should not be recruited into the study.

Keywords: seizures epilepsy
exercise activity intervention with sensor-based engagement in patients with atrial fibrillation

Conditions: Atrial Fibrillation; Arrhythmias, Cardiac; Cardiovascular Diseases

Summary: atrial fibrillation (af) affects 1 in 4 individuals during their lifetime and continues to increase in frequency and impact. exercise intervention has established benefits to improve af symptoms and burden in clinical studies. however, lack of access to exercise programs has limited therapeutic adoption. the growth of technology-driven health care and diagnostics, recognized as an emerging priority by the american heart association, offers an opportunity for a pragmatic and patient-centered approach to meet this need. ease-af is a prospective, interventional study with a sequential run-in control to evaluate if a digital health-driven, patient-centered exercise intervention improves af symptoms and burden. the research team will enroll 120 patients with symptomatic, paroxysmal af. the main impact of this study will be the establishment of evidence for a novel, pragmatic paradigm for a patient-centered, digital technology-driven personalized exercise intervention for patients with af.


Eligibility criteria:
inclusion criteria: * ≥40years of age * paroxysmal af * electrocardiographic (or equivalent) documentation of af within 12 months (would need to have evidence of af after initial post-ablation blanking period if the patient had prior af ablation) * af severity scale (afss) symptom score 13-26 * self-report weekly moderate-vigorous physical activity (mvpa) 30-120 minutes exclusion criteria: * unable to give consent * ≤90 days from af ablation, coronary revascularization, heart failure hospitalization * left ventricular ejection fraction (lvef) \<50%, moderate to severe stenotic valvular heart disease or severe regurgitant valvular disease or history of mechanical valve replacement, presence of implanted pacemaker or defibrillator system * labile inr or unable to take anticoagulant despite indication * life expectancy \< 1 year * hemodialysis; severe pulmonary or liver disease * musculoskeletal, balance/gait issues, severe peripheral vascular disease, or neuropathy or other neurologic conditions limiting exercise * self-report mvpa \<30 minutes * upon initial screening, if the participant's baseline fitbit-measured mvpa ≥180 minutes/week (despite self-report range of 30-120 minutes), the participant will be further excluded.

Keywords: atrial fibrillation physical activity exercise digital health intervention wearable technology symptoms quality of life